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creativecommons.org/licenses/by-nc-nd/Abstract Background: In the FLAURA trial, osimertinib demonstrated superior
progression-free survival and a favorable toxicity profile to erlotinib or gefitinib as initial ther-
apy in patients with EGFR-mutated advanced non-small-cell lung cancer. Patient-reported
outcomes from FLAURA are discussed here.
Methods: Patients (N Z 556) completed the EORTC QLQ-LC13 weekly for 6 weeks, then
every 3 weeks, and the QLQ-C30 every 6 weeks. Prespecified key symptoms were cough,
dyspnea, chest pain, appetite loss, and fatigue. Score changes from baseline to randomized
treatment discontinuation were assessed using a mixed-effects model. A 10-point change
was considered clinically relevant. Odds of improvement and time to deterioration were inves-
tigated. QLQ-C30 functioning scores were assessed post hoc.
Results: Questionnaire completion rates were >70% at most time points. Baseline mean scores
were similar in the osimertinib and erlotinib/gefitinib arms. Scores improved in both arms, but
none reached clinical relevance at 5% significance level. A statistically significant differencef Oncology, University of Turin, Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Regione Gon-
.
.it (S. Novello).
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
4.0/).
N.B. Leighl et al. / European Journal of Cancer 125 (2020) 49e5750favoring osimertinib for chest pain was not clinically relevant (6.84 vs 3.88; p Z 0.021).
Odds of improvement and time to deterioration were similar between treatments. In post
hoc analyses, improvements favored osimertinib for emotional functioning (8.79 vs 4.91;
p Z 0.004) and social functioning (7.66 vs 1.74; p < 0.001). Cognitive functioning remained
stable with osimertinib but deteriorated with erlotinib/gefitinib (0.03 vs 3.91; p Z 0.005).
Conclusions: Key symptoms improved from baseline in both treatment arms in FLAURA.
Key symptom improvements that were both statistically significant and clinically relevant were
not observed in favor of either treatment arm.
Clinical trial registration: NCT02296125
ª 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
For patients with advanced non-small-cell lung cancer
(NSCLC) and sensitizing epidermal growth factor
receptor mutations (EGFRm), the introduction of
targeted therapy with EGFRetyrosine kinase in-
hibitors (TKIs) has markedly improved clinical out-
comes [1e7].
Symptom management is crucial in the treatment of
patients with advanced NSCLC. Cough, dyspnea,
chest pain, fatigue, and appetite loss are key patient-
reported symptoms and have a marked negative
impact on health-related quality of life (HRQoL) [8,9].
Patients with advanced NSCLC who received first-
line treatment with erlotinib, gefitinib, or afatinib
experienced improvements in symptoms and HRQoL
compared with patients who received chemotherapy
[10e12]. In the LUX-Lung 7 trial that compared first-
line afatinib and gefitinib, similar improvements in
patient-reported outcomes (PROs) were observed in
both treatment arms [13]. In the ARCHER 1050 trial,
progression-free survival (PFS) and overall survival
(OS) were longer with dacomitinib than with gefitinib
in the first-line treatment of patients with NSCLC, but
improvements in global HRQoL were seen only with
gefitinib [6,14].
Osimertinib is an oral, irreversible, central nervous
system (CNS)-active, third-generation EGFR-TKI with
preclinical and clinical evidence of potent activity
against EGFRm NSCLC and the T790M resistance
mutation, the most common cause of resistance to early-
generation EGFR-TKIs [15e18]. The greater selectivity
for mutated EGFR and relative sparing of wild-type
EGFR also mean that osimertinib is associated with
less toxicity than earlier EGFR-TKIs [16]. In the phase 3
FLAURA trial of first-line treatment, osimertinib
significantly improved PFS compared with erlotinib or
gefitinib (18.9 months vs 10.2 months; hazard ratio
[HR]: 0.46; 95% confidence interval [CI]: 0.37e0.57;
p < 0.001) [16]. Rates for adverse events were lower with
osimertinib than with erlotinib/gefitinib for grade 3
(34% vs 45%) and for adverse events leading topermanent treatment discontinuation (13% vs 18%) [16].
Based on these results, osimertinib was approved as
first-line treatment for patients with EGFRm advanced
NSCLC and is recommended by National Comprehen-
sive Cancer Network guidelines as the preferred first-line
treatment for patients with EGFRm advanced or met-
astatic NSCLC [19].
PROs were part of secondary outcome measures in
the FLAURA trial and were assessed prospectively
using the European Organisation for Research and
Treatment of Cancer (EORTC) Quality of Life Ques-
tionnaire Lung Cancer 13 items (QLQ-LC13) and
Quality of Life Questionnaire Core 30 items (QLQ-
C30). The aim of the current analysis was to evaluate the
symptom burden in the FLAURA trial, in patients in
the osimertinib arm compared with those in the erloti-
nib/gefitinib arm.2. Methods
2.1. Study design and patients
FLAURA (NCT02296125) was a multinational, phase
3, double-blind, double-dummy, randomized trial [16].
The methods and primary efficacy results have been
reported in detail [16]. In brief, eligible patients had
locally advanced or metastatic EGFRm (exon 19 dele-
tion or L858R) NSCLC and were eligible for first-line
therapy with an EGFR-TKI. Patients were random-
ized 1:1 to receive oral osimertinib 80 mg once daily
(n Z 279) or either oral gefitinib 250 mg once daily or
oral erlotinib 150 mg once daily (n Z 277). The cut-off
date for the current analysis was 12 June 2017.
FLAURA was conducted in accordance with the
Declaration of Helsinki and is consistent with the
International Conference on Harmonisation and
Good Clinical Practice, applicable regulatory re-
quirements, and the AstraZeneca Bioethics Policy.
The study was approved by the institutional review
board and/or independent ethics committee associated
with each study center. All patients provided written
Table 1
EORTC QLQ-LC13 and QLQ-C30 scores at baseline.
QLQ-LC13 Osimertinib,
mean (SD)
Erlotinib/
gefitinib,
mean (SD)
Scale/items
Cougha 32.8 (27.2) 33.5 (28.8)
Hemoptysis 3.9 (14.3) 2.9 (10.7)
Dyspneaa 22.5 (23.1) 25.0 (22.8)
Sore mouth 4.4 (13.2) 5.2 (14.4)
Dysphagia 5.0 (14.0) 5.3 (13.9)
Peripheral neuropathy 6.6 (15.5) 10.1 (20.1)
Alopecia 5.1 (15.0) 6.4 (16.4)
Chest paina 19.5 (25.3) 20.8 (25.7)
Pain in arm or shoulder 17.6 (24.4) 19.1 (26.3)
Pain in other parts 23.3 (25.7) 22.4 (25.7)
Pain medication/help 60.1 (25.4) 62.6 (25.3)
QLQ-C30
Symptom scale/items
Fatiguea 32.2 (24.9) 35.8 (26.2)
Nausea and vomiting 7.3 (14.9) 7.2 (13.6)
Pain 25.8 (27.5) 27.2 (27.8)
Dyspnea 24.4 (28.4) 25.2 (27.8)
Insomnia 25.6 (27.9) 30.2 (28.4)
Appetite lossa 22.7 (28.5) 25.6 (29.9)
Constipation 13.3 (23.0) 16.2 (25.2)
Diarrhea 5.4 (14.6) 5.7 (15.1)
Financial difficulties 15.4 (24.3) 16.5 (26.7)
Global health status/QoL 62.5 (23.2) 58.8 (22.8)
Functional scales
Physical functioning 79.6 (21.6) 75.7 (21.0)
Role functioning 77.8 (28.2) 75.0 (29.1)
Emotional functioning 74.8 (20.0) 72.9 (22.1)
Cognitive functioning 86.5 (18.4) 84.6 (19.5)
Social functioning 80.6 (24.6) 77.3 (26.1)
EORTC, European Organisation for Research and Treatment of
Cancer; QLQ-LC13, Quality of Life Questionnaire Lung Cancer 13
items; QLQ-C30, Quality of Life Questionnaire Core 30 items; QoL,
quality of life; SD, standard deviation.
a Prespecified key symptom.
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were performed.
2.2. Questionnaires
Patients completed the questionnaires using electronic
devices. The EORTC QLQ-LC13 was completed at
baseline, then every week for 6 weeks, followed by every
3 weeks. The EORTC QLQ-C30 was completed at
baseline and then every 6 weeks. The EORTC QLQ-
LC13 is a 13-item lung-cancer-specific questionnaire
that measures disease-related symptoms and treatment-
related side effects [20]. The EORTC QLQ-C30 is a 30-
item cancer questionnaire that measures symptoms and
functional aspects commonly related to cancer [21]. An
outcome variable consisting of a score from 0 to 100 was
derived from each of the symptom scales and items in
the two questionnaires [20,21]. A higher score on the
symptom scale represents more/worse symptoms [20,21].
Higher functional scores represent a higher (“better”)
HRQoL or level of functioning [20,21]. For both ques-
tionnaires, a difference in score of at least 10 points was
considered clinically relevant, corresponding to at least a
moderate change in HRQoL [22].
The prespecified key symptoms of importance in
advanced NSCLC were cough, dyspnea, chest pain,
appetite loss, and fatigue [8,9]. Changes from baseline in
these symptoms were prespecified as key endpoints
(Supplementary Table 1).
Changes from baseline in QLQ-C30 global health
status/quality of life (QoL) and functioning from base-
line were assessed in a post hoc analysis.
2.3. Data analyses
Scores for EORTC QLQ-LC13 and QLQ-C30 pre-
specified key symptoms were summarized descriptively in
the full analysis set. The analyses for each item used all
data up to disease progression and beyond. Changes in
scores from baseline until randomized treatment discon-
tinuation were assessed using mixed-effects model for
repeated measures (MMRM) analysis. Missing data were
not imputed. The p value was determined using MMRM
analysis, with patient, treatment, visit, and treatment by
visit interaction as explanatory variables and baseline
symptom score and baseline symptom score by visit
interaction as covariates. Patient was fitted as a random
effect, and compound symmetry covariance structure was
used for all models. The mean differences for each
symptom are reported with corresponding 95% CIs. A
sensitivity analysis was conducted that used PRO data
from baseline to 9 months, and results were compared for
consistency with those from the main analysis.
The proportion of patients with clinically relevant
improvements in key symptoms, defined as a decrease in
score from baseline of at least 10 at two consecutive
assessments at least 21 days apart, was compared usinglogistic regression, with a factor for treatment arm.
Odds ratios with 95% CIs are reported.
Time-to-symptom deterioration, defined as time from
randomization until the date of the first clinically rele-
vant symptom deterioration or death from any cause,
was assessed for the five key symptoms until random-
ized treatment discontinuation, using KaplaneMeier
analysis. The difference in time-to-symptom deteriora-
tion was assessed by log-rank test, and p values are
reported.
Owing to the exploratory nature, all analyses must be
interpreted conservatively given the multiple scales, time
points, and hypotheses (a two-sided 5% significance level
has been used for interpretation purposes only, no
adjustments have been made for multiplicity).3. Results
The median duration of treatment was 16.2 months in
the osimertinib arm and 11.5 months in the erlotinib/
N.B. Leighl et al. / European Journal of Cancer 125 (2020) 49e5752gefitinib arm at the time of data cut-off [16]. The median
duration of follow-up for PFS was 15.0 months in the
osimertinib arm and 9.7 months in the erlotinib/gefitinib
arm [16]. Ninety-one (66.9%) patients in the osimertinib
arm and 145 (70.4%) patients in the erlotinib/gefitinib
arm remained on randomized treatment after progres-
sion, for a similar length of time.3.1. Questionnaire completion rates
Questionnaire completion rates at baseline were >90%
in both arms. Completion rates declined faster in the
erlotinib/gefitinib arm than in the osimertinib arm, likely
reflecting differences in PFS rates between the two
treatment arms (Supplementary Tables 2 and 3).3.2. Baseline symptoms
Mean key symptom scores at baseline were low and
similar in the osimertinib and erlotinib/gefitinib arms
(Table 1). Many patients responded “not at all” to the
key symptom severity questions, and most patients who
reported baseline symptoms graded their severity as “a
little” (Fig. 1). The proportion of patients reporting at
least “a little” severity was lowest for “dyspnea whenProportion of patients with at least “a little” symptom severity
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Fig. 1. Proportion of patients in the osimertinib and erlotinib/gefitin
symptom severity. E/G, erlotinib/gefitinib; Osi, osimertinib.rested” (osimertinib: 23.0%; erlotinib/gefitinib: 30.3%)
and highest for “felt tired” (66.3% vs 70.8%) (Fig. 1).
3.3. Changes from baseline
Key symptoms improved from baseline until treatment
discontinuation in both groups (Table 2). None of the
improvements in key symptoms reached the predefined
10-point threshold for clinical relevance at 5% signifi-
cance level. For chest pain, improvements from baseline
were statistically significantly better with osimertinib
than with erlotinib/gefitinib (mean change in score:
6.84 vs 3.88; estimated difference: 2.96; 95% CI:
5.47, 0.45; p Z 0.021). Improvements in cough were
seen as early as week 1 in both treatment arms (mean
change in score, osimertinib: e6.6; erlotinib/gefitinib:
4.9) and were maintained throughout the study period.
Results from the sensitivity analysis using data from
baseline to 9 months were consistent with those from the
main analysis, except for chest pain (Supplementary
Table 4).
Similar proportions of patients in the two treatment
arms had clinically relevant improvements in key
symptoms during randomized treatment. No significant
difference in odds of improvement of prespecified key
symptoms was detected (Fig. 2).Not at all
Symptom severity at baseline:
When
mbing stairs
Need to
rest
Felt weak Felt tired
Fatigue Appetite
loss
59.5%
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61.3%
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66.3%
70.8%
43.8%
47.6%
A little
Quite a bit
Very much
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ib arms reporting key symptoms at baseline, shown by reported
Table 2
Changes in key patient-reported symptom scores over time from baseline until randomized treatment discontinuation, assessed using MMRM
analysisa.
Symptom Treatment Adjusted mean (95% CI) Estimated treatment differenceb (95% CI) p value
Cough Osimertinib 10.14 (12.12, 8.16) 1.96 (4.83, 0.91) 0.180
Erlotinib/gefitinib 8.18 (10.25, 6.10)
Dyspnea Osimertinib 3.19 (4.92, 1.47) 1.99 (4.45, 0.47) 0.113
Erlotinib/gefitinib 1.20 (2.95, 0.54)
Chest pain Osimertinib 6.84 (8.58, 5.10) 2.96 (5.47, 0.45) 0.021
Erlotinib/gefitinib 3.88 (5.69, 2.07)
Fatigue Osimertinib 3.30 (5.45, 1.16) 0.01 (3.22, 3.25) 0.993
Erlotinib/gefitinib 3.32 (5.68, e0.95)
Appetite loss Osimertinib 5.81 (8.24, 3.39) 1.46 (5.08, 2.15) 0.427
Erlotinib/gefitinib 4.35 (7.04, 1.66)
CI, confidence interval; MMRM, mixed-effects model for repeated measures.
Note: Owing to the exploratory nature, all analyses must be interpreted conservatively given the multiple scales, time points, and hypotheses
(a two-sided 5% significance level has been used for interpretation purposes only; no adjustments have been made for multiplicity).
a The p value was determined using MMRM analysis, with patient, treatment, visit, and treatment by visit interaction as explanatory variables
and with baseline symptom score and baseline symptom score by visit interaction as covariates. Patient was fitted as a random effect, and
compound symmetry covariance structure was used for all models.
b Osimertinib minus erlotinib/gefitinib. A difference of less than 0 favors osimertinib for symptom scales.
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relevant symptom deterioration event from randomiza-
tion until randomized treatment discontinuation was the
lowest for chest pain (osimertinib: 37.3%; erlotinib/
gefitinib: 33.6%) and highest for dyspnea (osimertinib:
57.0%; erlotinib/gefitinib: 56.3%) (Table 3). For patients
with a clinically relevant deterioration event, the median
time from randomization to the first event was similar in
the two treatment arms, with overlapping 95% CIs for
medians (Table 3 and Supplementary Fig. 1).
Improvements in global health status/QoL and
functional scores from baseline to randomized treatment
discontinuation were seen in both treatment arms
(Fig. 3). Improvements in the osimertinib arm were
statistically significantly greater than in the erlotinib/
gefitinib arm for emotional functioning (8.79 vs 4.91;
p Z 0.004) and social functioning (7.66 vs 1.74;
p < 0.001). Cognitive functioning remained stable in the
osimertinib arm but deteriorated in the erlotinib/gefiti-
nib arm (0.03 vs 3.91; p Z 0.005). None of the mean
changes reached the 10-point improvement threshold for
clinical relevance.4. Discussion
In the FLAURA trial, first-line treatment with osi-
mertinib demonstrated superior efficacy to erlotinib or
gefitinib in patients with EGFRm advanced NSCLC,
including in patients with CNS metastases at trial entry
[16]. The PRO analyses presented here show improve-
ments in key lung cancer symptoms in both treatment
arms from baseline until randomized treatment discon-
tinuation. Statistically significant differences in favor of
osimertinib were observed for changes from baseline in
chest pain, and emotional, social, and cognitivefunctioning, although these differences did not meet the
predefined threshold for clinical relevance.
The overall burden of key lung cancer symptoms was
low at baseline, with most patients in both treatment
arms reporting symptom severity of “not at all” or “a
little.” The low baseline symptom burden, which is
common in patients receiving first-line treatment for
NSCLC [23], poses technical challenges in the mea-
surement of improvements. A 10-point change in QLQ-
C30 score is commonly used as the minimal clinically
important difference in phase 3 advanced NSCLC trials
[24]. However, results from the French Cooperative
Thoracic Intergroup (IFCT) indicate that a lower, 5-
point cut-off could be clinically relevant [25]. Use of
the IFCT definition for the data reported here reveals
clinically relevant improvements during randomized
treatment in both arms for cough and in the osimertinib
arm for chest pain, appetite loss, global health status/
QoL, and emotional and social functioning.
Only one-third to just over half of patients remaining
on protocol therapy in the current analysis experienced
a clinically relevant deterioration in key lung cancer
symptoms at any time from randomization to random-
ized treatment discontinuation. Among patients who
experienced a clinically relevant deterioration in symp-
toms, the time to the first recorded event was similar in
the two treatment arms. A challenge in clinical oncology
research is the lack of a standardized definition or
method of analysis for deterioration. Patients may
experience only asymptomatic progression such as
radiological progression (e.g. a new asymptomatic
lesion) or symptomatic progression involving nonkey
symptoms (e.g. due to CNS metastasis). In FLAURA,
sites of progression differed between treatment arms.
Furthermore, patients in the erlotinib/gefitinib arm
progressed significantly earlier than those in the osi-
mertinib arm, making those remaining on treatment
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Fig. 2. Proportion of patients with clinically relevant improvements in key symptoms. CI, confidence interval; E/G, erlotinib/gefitinib.
The symptom improvement rate was based on a decrease in score from baseline 10 at two consecutive assessments 21 days apart.
The denominator n is all patients with nonmissing baseline values.
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the time to deterioration analysis.
The FLAURA trial showed a significant and clini-
cally meaningful improvement in PFS of osimertinib
compared with standard of care (18.9 months vs 10.2
months), but with no clinically meaningful difference
between arms in key symptoms. There may be a few
reasons for this apparent disparity. PFS is measured by
radiological progression (increase in tumor size; new
lesion). Progression can be asymptomatic, depending on
the location and nature of the tumor(s) leading to pro-
gression, and it is common practice for patients to
continue treatment in such cases. In this trial, approxi-
mately 70% of patients continued randomized treatment
beyond progression in both treatment arms for a similar
median duration. If a progression event is symptomatic,
it may lead to symptoms that are not detected in the
PRO data or to a small increase in symptoms that is not
considered clinically meaningful using current analytical
methods.Table 3
Time to deterioration in key patient-reported symptom scores from baselin
Symptom Treatment Patients with deterioration
event, n (%)b
Cough Osimertinib 109 (44.0)
Erlotinib/gefitinib 113 (44.8)
Dyspnea Osimertinib 159 (64.1)
Erlotinib/gefitinib 156 (61.9)
Chest pain Osimertinib 104 (41.9)
Erlotinib/gefitinib 93 (36.9)
Fatigue Osimertinib 150 (58.1)
Erlotinib/gefitinib 138 (53.7)
Appetite loss Osimertinib 110 (42.6)
Erlotinib/gefitinib 102 (39.7)
CI, confidence interval; NR, not reached.
a KaplaneMeier analysis. Time-to-symptom deterioration was defined
relevant symptom deterioration (an increase in the score from baseline 1
b The denominator n is all patients with nonmissing baseline values.In the FLAURA trial, 19% of patients in the osi-
mertinib arm and 23% in the erlotinib/gefitinib arm had
known or treated CNS metastases at trial entry [16].
Irrespective of status of CNS metastases at baseline, the
rate of CNS progression was higher in the erlotinib/
gefitinib arm (15%) than in the osimertinib arm (6%)
[16]. Cognitive function deteriorated in the erlotinib/
gefitinib arm in the current analysis but did not change
from baseline in the osimertinib arm, which may reflect
differences in CNS progression between the two treat-
ment arms.
In real-world management of patients with advanced
NSCLC, incremental gains in PFS or OS are regarded as
clinically meaningful only if they are achieved without a
marked negative effect on HRQoL [26]. As such, it is
important to record PROs (symptoms, function,
HRQoL) in trials. Results from FLAURA demonstrate
that the efficacy of osimertinib was superior to that of
first- and second-generation EGFR-TKIs, without
increased toxicity [16]. Improvements in key lung cancere to discontinuation of randomized treatmenta.
Median time to
deterioration (95% CI)
Probability of no
deterioration (%)
at 6 months at 12 months
NR (9.92eNR) 63.08 55.44
13.08 (8.25eNR) 58.88 52.45
2.79 (1.38e6.18) 44.00 33.41
4.14 (2.00e6.90) 44.85 37.23
21.36 (15.24eNR) 67.65 59.95
NR (16.53eNR) 67.21 60.83
6.87 (4.17e11.01) 50.59 41.66
8.25 (5.62e10.61) 56.76 39.13
NR (13.77eNR) 69.46 59.93
15.24 (11.01eNR) 65.12 56.49
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Fig. 3. Changes in global health status/QoL and functioning scores from baseline until discontinuation of randomized treatment, assessed
using MMRM analysis. Error bars denote standard errors. CI, confidence interval; E/G, erlotinib/gefitinib; MMRM, mixed-effects model
for repeated measures, QoL, quality of life. p values were determined using an MMRM analysis, with patient, treatment, visit, and
treatment by visit interaction as explanatory variables and baseline symptom score and baseline symptom score by visit interaction as
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effect. Compound symmetry was used as the covariance structure for all models. A difference higher than 0 favors osimertinib for global
health status/QoL and functional scales.
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were observed up to treatment discontinuation, with the
median duration of response approximately twice as
long in the osimertinib arm as in the erlotinib/gefitinib
arm [16].
The FLAURA PRO assessments had several
strengths. The EORTC QLQ-LC13 and QLQ-C30
questionnaires are well established and widely used in
advanced NSCLC treatment trials [11,27e30], and have
been thoroughly validated [20,21,31]. Questionnaire
completion rates were high, with more than 70% of
patients in both treatment arms completing the ques-
tionnaires at most time points. Data for PRO assess-
ments were collected at a large number of time points.
The current report highlights limitations inherent to
trials of targeted therapy in advanced NSCLC, including
the need to identify the most appropriate analyses for
time to deterioration and CNS progression when disease
and therapy burden may be low. The current report does
not include an analysis of whether CNS metastases were
associated with differences in PROs. The MMRM
analysis used all available data, which assumes that
characteristics of patients with incomplete questionnaires
were similar to those with complete questionnaires.
PROs were secondary outcome measures in FLAURA,
and, as such, the trial was not powered for each PROhypothesis. PRO results should thus be interpreted with
caution and are considered exploratory.
In conclusion, PRO results from FLAURA show
improvements from baseline in key lung cancer symp-
toms in both treatment arms. Improvements in key
symptoms that were both statistically significant and
clinically relevant were not observed in favor of either
treatment arm. Further work may be beneficial to
explore the effects of CNS metastases on PROs and
definitions of improvement and deterioration.
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